[1] Browett P J, et al. Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: interim data from a phase 2 open-label proof-of-concept study[J]. Blood, 2022, 140(Supplement 1): 717-719.
[2] Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. 2024 May 16:1-11. DOI:
10.1080/03007995.2024.2354533[3] Versino F, et al. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. Int J Lab Hematol. 2024 May;46 Suppl 1:43-54. DOI:
10.1111/ijlh.14281[4] Prasad RR, et al. An intracellular complement system drives metabolic and proinflammatory reprogramming of vascular fibroblasts in pulmonary hypertension. JCI Insight. 2025 Feb 13;10(6):e184141. DOI:
10.1172/jci.insight.184141